Shire Orphan Therapies Gmbh

Alcon Research, Ltd.

Shire Orphan Thereapies Gmbh

Takeda Pharmaceutical Company Limited

Markus Woischnik

Ulrich Reineke

Frank Osterkamp

Ulf Reimer

Gerd Hummel

Uwe Richter

Edgar Specker

Bernadett Simon

Heiko Hawlisch

Tobias Knaute

Mark R Hellberg

Mark R Helberg

Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.

NPR-B agonists

Disclosed are cyclic, peptide-based novel compounds having NPR-B agonistic activity. Preferred compounds are cyclic peptides containing conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds. In some embodiments, provided herein are a cyclic peptide compound with a ring size that is significantly reduced as compared to known NPR-B agonists, such as CNP.

Cyclic peptide-based NPR-B agonists

Growing community of inventors

Berlin, Germany

Markus Woischnik